Skip to main content
Erschienen in: AIDS and Behavior 4/2020

08.07.2019 | Original Paper

HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort)

verfasst von: Melina Erica Santos, Camelia Protopopescu, Philippe Sogni, Issifou Yaya, Lionel Piroth, François Bailly, Fabienne Marcellin, Laure Esterle, Linda Wittkop, Eric Rosenthal, Philippe Morlat, Perrine Roux, Wildo Navegantes de Araujo, Dominique Salmon-Ceron, Maria Patrizia Carrieri, the ANRS CO13 HEPAVIH Study Group

Erschienen in: AIDS and Behavior | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Mortality among individuals co-infected with HIV and hepatitis C virus (HCV) is relatively high. We evaluated the association between psychoactive substance use and both HCV and non-HCV mortality in HIV/HCV co-infected patients in France, using Fine and Gray’s competing-risk model adjusted for socio-demographic, clinical predictors and confounding factors, while accounting for competing causes of death. Over a 5-year median follow-up period, 77 deaths occurred among 1028 patients. Regular/daily cannabis use, elevated coffee intake, and not currently smoking were independently associated with reduced HCV-mortality (adjusted sub-hazard ratio [95% CI] 0.28 [0.10–0.83], 0.38 [0.15–0.95], and 0.28 [0.10–0.79], respectively). Obesity and severe thinness were associated with increased HCV-mortality (2.44 [1.00–5.93] and 7.25 [2.22–23.6] versus normal weight, respectively). Regular binge drinking was associated with increased non-HCV-mortality (2.19 [1.10–4.37]). Further research is needed to understand the causal mechanisms involved. People living with HIV/HCV co-infection should be referred for tobacco, alcohol and weight control interventions and potential benefits of cannabis-based therapies investigated.
Literatur
1.
Zurück zum Zitat Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, et al. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4 + T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: a MASTER cohort study. Medicine. 2016;95:e4091.CrossRef Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, et al. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4 + T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: a MASTER cohort study. Medicine. 2016;95:e4091.CrossRef
2.
Zurück zum Zitat Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Med. 2015;16:230–9.CrossRef Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Med. 2015;16:230–9.CrossRef
3.
Zurück zum Zitat Rallón N, García M, García-Samaniego J, Rodríguez N, Cabello A, Restrepo C, et al. HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. PLoS ONE. 2017;12:e0173943.CrossRef Rallón N, García M, García-Samaniego J, Rodríguez N, Cabello A, Restrepo C, et al. HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. PLoS ONE. 2017;12:e0173943.CrossRef
4.
Zurück zum Zitat Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, et al. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int. 2017;37:1526–34.CrossRef Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, et al. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int. 2017;37:1526–34.CrossRef
6.
Zurück zum Zitat Cerrato E, Calcagno A, D’Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Hear. 2015;2:e000174.CrossRef Cerrato E, Calcagno A, D’Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Hear. 2015;2:e000174.CrossRef
7.
Zurück zum Zitat Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6:266–71.CrossRef Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6:266–71.CrossRef
8.
Zurück zum Zitat Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int. 2015;35:65–70.CrossRef Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int. 2015;35:65–70.CrossRef
9.
Zurück zum Zitat Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28:1181–91.CrossRef Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28:1181–91.CrossRef
10.
Zurück zum Zitat Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med. 2009;10:282–9.CrossRef Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med. 2009;10:282–9.CrossRef
11.
Zurück zum Zitat Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590–8.CrossRef Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590–8.CrossRef
12.
Zurück zum Zitat Weill-Barillet L, Pillonel J, Semaille C, Léon L, Le Strat Y, Pascal X, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique. 2016;64(4):31–312.CrossRef Weill-Barillet L, Pillonel J, Semaille C, Léon L, Le Strat Y, Pascal X, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique. 2016;64(4):31–312.CrossRef
14.
Zurück zum Zitat Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, et al. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med. 2017;15:1–11.CrossRef Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, et al. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med. 2017;15:1–11.CrossRef
16.
Zurück zum Zitat Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, et al. Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up. AIDS. 2019;33:1013–22.CrossRef Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, et al. Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up. AIDS. 2019;33:1013–22.CrossRef
17.
Zurück zum Zitat Costiniuk CT, Brunet L, Rollet-Kurhajec KC, Cooper CL, Walmsley SL, Gill MJ, et al. Tobacco smoking is not associated with accelerated liver disease in human immunodeficiency virus-hepatitis C coinfection: a longitudinal cohort analysis. In: Open Forum Infectious Diseases; 2016. p. ofw050. Costiniuk CT, Brunet L, Rollet-Kurhajec KC, Cooper CL, Walmsley SL, Gill MJ, et al. Tobacco smoking is not associated with accelerated liver disease in human immunodeficiency virus-hepatitis C coinfection: a longitudinal cohort analysis. In: Open Forum Infectious Diseases; 2016. p. ofw050.
18.
Zurück zum Zitat Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRef Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRef
19.
Zurück zum Zitat Osna NA, Donohue TM, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38:147–61.PubMedPubMedCentral Osna NA, Donohue TM, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38:147–61.PubMedPubMedCentral
21.
Zurück zum Zitat Eyawo O, McGinnis KA, Justice AC, Fiellin DA, Hahn JA, Williams EC, et al. Alcohol and mortality: combining self-reported (AUDIT-C) and biomarker detected (PEth) alcohol measures among HIV infected and uninfected. J Acquir Immune Defic Syndr. 2018;77:135–43.CrossRef Eyawo O, McGinnis KA, Justice AC, Fiellin DA, Hahn JA, Williams EC, et al. Alcohol and mortality: combining self-reported (AUDIT-C) and biomarker detected (PEth) alcohol measures among HIV infected and uninfected. J Acquir Immune Defic Syndr. 2018;77:135–43.CrossRef
23.
Zurück zum Zitat Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, et al. Cannabis use and reduced risk of insulin resistance in HIV-HCV infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Clin Infect Dis. 2015;61:40–8.CrossRef Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, et al. Cannabis use and reduced risk of insulin resistance in HIV-HCV infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Clin Infect Dis. 2015;61:40–8.CrossRef
27.
Zurück zum Zitat Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, et al. Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31:149–56.CrossRef Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, et al. Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31:149–56.CrossRef
28.
Zurück zum Zitat Loko M-A, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010. BMC Infect Dis. 2010;10:303.CrossRef Loko M-A, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010. BMC Infect Dis. 2010;10:303.CrossRef
29.
Zurück zum Zitat Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, et al. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients’ beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res. 2012;12:59.CrossRef Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, et al. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients’ beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res. 2012;12:59.CrossRef
30.
Zurück zum Zitat Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRef Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRef
31.
Zurück zum Zitat Roux P, Lions C, Cohen J, Winnock M, Salmon-Céron D, Bani-Sadr F, et al. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther. 2014;19:171–8.CrossRef Roux P, Lions C, Cohen J, Winnock M, Salmon-Céron D, Bani-Sadr F, et al. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther. 2014;19:171–8.CrossRef
32.
Zurück zum Zitat Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’autoévaluation. Eur Psychiatry. 1989;4:163–6. Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’autoévaluation. Eur Psychiatry. 1989;4:163–6.
35.
Zurück zum Zitat Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanashian G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50:1368–81.CrossRef Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanashian G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50:1368–81.CrossRef
36.
Zurück zum Zitat Brunet L, Moodie EEM, Rollet K, Cooper C, Walmsley S, Potter M, et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal Cohort analysis. Clin Infect Dis. 2013;57:663–70.CrossRef Brunet L, Moodie EEM, Rollet K, Cooper C, Walmsley S, Potter M, et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal Cohort analysis. Clin Infect Dis. 2013;57:663–70.CrossRef
39.
Zurück zum Zitat Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011;18:1099–111.CrossRef Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011;18:1099–111.CrossRef
41.
Zurück zum Zitat Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B, et al. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology. 2012;56:2010.CrossRef Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B, et al. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology. 2012;56:2010.CrossRef
42.
Zurück zum Zitat Klein MB, Rollet-Kurhajec KC, Moodie EEM, Yaphe S, Tyndall M, Walmsley S, et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013). AIDS. 2014;28:1957–65.CrossRef Klein MB, Rollet-Kurhajec KC, Moodie EEM, Yaphe S, Tyndall M, Walmsley S, et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013). AIDS. 2014;28:1957–65.CrossRef
45.
Zurück zum Zitat Kee CC, Sumarni MG, Lim KH, Selvarajah S, Haniff J, Tee GHH, et al. Association of BMI with risk of CVD mortality and all-cause mortality. Public Health Nutr. 2017;20:1226–34.CrossRef Kee CC, Sumarni MG, Lim KH, Selvarajah S, Haniff J, Tee GHH, et al. Association of BMI with risk of CVD mortality and all-cause mortality. Public Health Nutr. 2017;20:1226–34.CrossRef
46.
Zurück zum Zitat Park D, Lee J-H, Han S. Underweight: another risk factor for cardiovascular disease? A cross-sectional 2013 Behavioral Risk Factor Surveillance System (BRFSS) study of 491,773 individuals in the USA. Medicine. 2017;96:e8769.CrossRef Park D, Lee J-H, Han S. Underweight: another risk factor for cardiovascular disease? A cross-sectional 2013 Behavioral Risk Factor Surveillance System (BRFSS) study of 491,773 individuals in the USA. Medicine. 2017;96:e8769.CrossRef
48.
Zurück zum Zitat Thomson H, Thomas S, Sellstrom E, Petticrew M. Housing improvements for health and associated socio-economic outcomes. Cochrane Database Syst Rev. 2013;28:008657. Thomson H, Thomas S, Sellstrom E, Petticrew M. Housing improvements for health and associated socio-economic outcomes. Cochrane Database Syst Rev. 2013;28:008657.
49.
Zurück zum Zitat Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend. 2016;161:95–103.CrossRef Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend. 2016;161:95–103.CrossRef
50.
Zurück zum Zitat Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200–7.CrossRef Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200–7.CrossRef
52.
Zurück zum Zitat Lopez-Pelayo H, Batalla A, Balcells MM, Colom J, Gual A. Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. Psychol Med. 2015;45:1121–33.CrossRef Lopez-Pelayo H, Batalla A, Balcells MM, Colom J, Gual A. Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. Psychol Med. 2015;45:1121–33.CrossRef
Metadaten
Titel
HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort)
verfasst von
Melina Erica Santos
Camelia Protopopescu
Philippe Sogni
Issifou Yaya
Lionel Piroth
François Bailly
Fabienne Marcellin
Laure Esterle
Linda Wittkop
Eric Rosenthal
Philippe Morlat
Perrine Roux
Wildo Navegantes de Araujo
Dominique Salmon-Ceron
Maria Patrizia Carrieri
the ANRS CO13 HEPAVIH Study Group
Publikationsdatum
08.07.2019
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 4/2020
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02585-7

Weitere Artikel der Ausgabe 4/2020

AIDS and Behavior 4/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.